Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy

Melike Ersoy; Hamide Pişkinpaşa

doi:10.1515/jpem-2021-0664

Article

Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy

Melike Ersoy and Hamide Pişkinpaşa

Published/Copyright: March 3, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Journal of Pediatric Endocrinology and Metabolism Volume 35 Issue 4

Abstract

Objectives

Gaucher disease type 1 (GD1) and Fabry disease (FD) are the two most common lysosomal storage diseases. For over three decades, effective enzyme replacement therapies (ERTs) have changed the fate of patients and offered a longer chance of survival and improve their quality of life.

Methods

The clinical and molecular findings, endocrinological features and metabolic status of 26 patients (16 with FD, and 10 with GD1) were evaluated. The results were compared to age- and gender-matched healthy individuals.

Results

Patients with GD1 and FD were followed for 7.2 ± 4.7 and 6.4 ± 4.3 years, respectively. Calcium and magnesium levels in patients with GD1 were lower than in controls (p=0.01; p=0.002). Osteoporosis was detected in 20% (n=2) of GD1 patients and 12.5% (n=2) of FD patients. The HbA1c value of GD1 patients was significantly lower than both in control and Fabry patients (p=0.004; and p=0.007, respectively). There was a negative correlation between LysoGb3 and female gender (p=0.04; r=−0.49), but no correlation was found with any other biochemical parameters. There was a negative correlation between the LysoGb1 level and the neutrophil (p=0.03; r=−0.711) and thrombocyte levels (p=0.02; r=−0.767), and a positive correlation with ferritin levels (p<0.001; r=0.867).

Conclusion

Long time effective ERT seems to have beneficial effects on metabolic and hormonal status as well as primary target organs in both FD and GD1 patients.

Keywords: endocrinology; Fabry disease; Gaucher disease

Corresponding author: Melike Ersoy, Department of Pediatrics, Division of Pediatric Metabolism, Health Sciences University, Bakirkoy Dr. Sadi Konuk Research and Education Hospital, Istanbul, Turkey, Phone: +90 5334205059, E-mail: zeynepcey@hotmail.com

Acknowledgments

We thank the patients and family members who participated in this study.

Research funding: None declared.
Author contributions: Concept: M.E, H.P; Design: M.E, H.P; Data Collection M.E, H.P; Analysis or Interpretation: M.E, H.P; Writing: M.E, H.P. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Conflict of interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: It was approved by the Ethics Committee of the Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey (Approval number:2021-12-08; date: 21/06/2021).

References

1. Ferraz, MJ, Kallemeijn, WW, Mirzaian, M, Herrera Moro, D, Marques, A, Wisse, P, et al.. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta Mol Cell Biol Lipids BBA-Mol Cell Biol L 2014;1841:811–25. https://doi.org/10.1016/j.bbalip.2013.11.004.Search in Google Scholar PubMed

2. Zimran, A, Elstein, D. Gaucher disease and related lysosomal storage diseases. In: Kaushansky, K, Lichtman, M, Prchal, J, Levi, MM, Press, O, Burns, L, et al.., editors. Williams hematology, 9th ed. New York, NY, USA: McGraw-Hill; 2016.Search in Google Scholar

3. Aerts, J, Kuo, CL, Lelieveld, LT, Boer, DEC, van der Lienden, MJC, Overkleeft, HS, et al.. Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease. Curr Opin Chem Biol 2019;53:204–15. https://doi.org/10.1016/j.cbpa.2019.10.006.Search in Google Scholar PubMed

4. Dutra-Clarkea, M, Tapiaa, D, Curtina, E, Rünger, D, Leea, GK, Lakatosa, A, et al.. Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy. Mol Genet Metab Rep 2021;26:100700. https://doi.org/10.1016/j.ymgmr.2020.100700.Search in Google Scholar PubMed PubMed Central

5. Eng, CM, Germain, DP, Banikazemi, M, Warnock, DGC, Wanner, RJ, Hopkin, J, et al.. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539–48. https://doi.org/10.1097/01.gim.0000237866.70357.c6.Search in Google Scholar PubMed

6. Cozma, C, Cullufi, P, Kramp, G, Hovakimyan, M, Velmishi, V, Gjikopulli, A, et al.. Treatment efficiency in Gaucher patients can reliably be monitored by quantification of lyso-Gb1 concentrations in dried blood spots. Int J Mol Sci 2020;21:4577. https://doi.org/10.3390/ijms21134577.Search in Google Scholar PubMed PubMed Central

7. Nowak, A, Beuschlein, F, Sivasubramaniam, V, Kasper, D, Warnock, DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet 2021;0:1–7. https://doi.org/10.1136/jmedgenet-2020-107338.Search in Google Scholar PubMed PubMed Central

8. Revel-Vilk, S, Fuller, M, Zimran, A. Value of Glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review. Int J Mol Sci 2020;21:7159. https://doi.org/10.3390/ijms21197159.Search in Google Scholar PubMed PubMed Central

9. Ghauharali-van der Vlugt, K, Langeveld, M, Poppema, A, Kuiper, S, Hollak, CE, Aerts, JM, et al.. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 2008;389:109–13. https://doi.org/10.1016/j.cca.2007.12.001.Search in Google Scholar PubMed

10. World Health Organization (WHO). WHO scientific group on the assessment of osteoporosis at the primary health care level: summary meeting report. Available at: https://www.who.int/chp/topics/Osteoporosis.pdf [Accessed 57 May 2004].Search in Google Scholar

11. Hauser, AC, Gessl, A, Lorenz, M, Voigtländer, T, Födinger, M, Sunder-Plassmann, G. High prevalence of subclinical hypothyroidism in patients with Anderson–Fabry disease. J Inherit Metab Dis 2005;28:715–22. https://doi.org/10.1007/s10545-005-0003-3.Search in Google Scholar PubMed

12. Faggiano, A, Pisani, A, Milone, F, Gaccione, M, Filippella, M, Santoro, A, et al.. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab 2006;91:4319–25. https://doi.org/10.1210/jc.2006-0858.Search in Google Scholar PubMed

13. Murugesan, V, Chuang, WL, Liu, J, Lischuk, A, Kacena, K, Lin, H, et al.. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol 2016;91:1082–9. https://doi.org/10.1002/ajh.24491.Search in Google Scholar

14. Hauser, AC, Gessl, A, Harm, F, Wiesholzer, M, Kleinert, J, Wallner, M, et al.. Hormonal profile and fertility in patients with Anderson–Fabry disease. Int J Clin Pract 2005;59:1025–8. https://doi.org/10.1111/j.1742-1241.2005.00620.x.Search in Google Scholar

15. Dumont, JE, Lamy, F, Roger, P, Maenhaut, C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992;72:667–97. https://doi.org/10.1152/physrev.1992.72.3.667.Search in Google Scholar

16. Zimran, A, Abrahamov, A, Elstein, D. Children with type I Gaucher disease: Growing into adulthood with and without enzyme therapy. Isr Med Assoc J 2000;2:80–1.Search in Google Scholar

17. Langeveld, M, Fost, M, Aerts, JMFG, Sauerwein, HP, Hollak, CEM. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood Cells Mol Dis 2008;40:428–32. https://doi.org/10.1016/j.bcmd.2007.09.002.Search in Google Scholar

18. Szurkowska, M, Szafraniec, K, Gilis-Januszewska, A, Szybinski, Z, Huszno, B. Insulin resistance indices in population-based study and their predictive value in defining metabolic syndrome. Przegl Epidemiol 2005;59:743–51.10.1097/00001648-200509000-00330Search in Google Scholar

19. Fuller, M. Sphingolipids: the nexus between Gaucher disease and insulin resistance. Lipids Health Dis 2010;9:113. https://doi.org/10.1186/1476-511x-9-113.Search in Google Scholar

20. Lorenz, F, Pawlowicz, E, Klimkowska, M, Beshara, S, Bulanda Brustad, A, Skotnicki, AB, et al.. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells Mol Dis 2018;68:35–42. https://doi.org/10.1016/j.bcmd.2016.10.010.Search in Google Scholar

21. Alfonso, P, Cenarro, A, Perez-Calvo, JI, Puzo, J, Giralt, M, Giraldo, P, et al.. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher’s disease. Med Clin (Barc) 2003;120:641–6. https://doi.org/10.1016/s0025-7753(03)73797-x.Search in Google Scholar

22. Stein, P, Yang, R, Liu, J, Pastores, DM, Mistry, PK. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis 2011;34:429–37. https://doi.org/10.1007/s10545-010-9271-7.Search in Google Scholar PubMed PubMed Central

23. Zimmermann, A, Grigorescu-Sido, P, Rossmann, H, Lackner, KJ, Drugan, C, Al Khzouz, C, et al.. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study. J Inherit Metab Dis 2013;36:555–63. https://doi.org/10.1007/s10545-012-9529-3.Search in Google Scholar PubMed

24. de Fost, M, Langeveld, M, Franssen, R, Hutten, BA, Groener, JE, de Groot, E, et al.. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. Atherosclerosis 2009;204:267–72. https://doi.org/10.1016/j.atherosclerosis.2008.08.027.Search in Google Scholar

25. Greenwood, A, Elstein, D, Ari Zimran, A, Altarescu, G. Effect of vitamin D receptor (VDR) genotypes on the risk for osteoporosis in type 1 Gaucher disease. Clin Rheumatol 2010;29:1037–41. https://doi.org/10.1007/s10067-010-1464-9.Search in Google Scholar

26. Lebel, E, Dweck, A, Foldes, AJ, Golowa, Y, Itzchaki, M, Zimran, A, et al.. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metabol 2004;22:597–601. https://doi.org/10.1007/s00774-004-0529-8.Search in Google Scholar

27. Hughes, D, Cappellini, MD, Berger, M, Van Droogenbroeck, J, de Fost, M, Janic, D, et al.. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007;138:676–86. https://doi.org/10.1111/j.1365-2141.2007.06701.x.Search in Google Scholar

28. Stirnemann, J, Belmatoug, N, Camou, F, Serratrice, C, Froissart, R, Caillaud, C, et al.. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017;18:441. https://doi.org/10.3390/ijms18020441.Search in Google Scholar

29. Rusinska, A, Pludowski, P, Walczak, M, Borszewska-Kornacka, MK, Bossowski, A, Chlebna-Sokol, D, et al.. Vitamin D supplementation guidelines for General population and groups at risk of vitamin D deficiency in Poland recommendations of the polish society of pediatric endocrinology and diabetes and the expert panel with participation of national specialist consultants and representatives of scientific societies-2018 update. Front Endocrinol (Lausanne) 2018;9:246.10.3389/fendo.2018.00246Search in Google Scholar

30. Mersebach, H, Johansson, JO, Rasmussen, ÅK, Bengtsson, BÅ, Rosenberg, K, Hasholt, L, et al.. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 2007;9:812–8. https://doi.org/10.1097/gim.0b013e31815cb197.Search in Google Scholar

31. Kałużna, M, Trzeciak, I, ZiemnickaK, Machaczka, M, Ruchała, M. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis 2019;14:275. https://doi.org/10.1186/s13023-019-1211-5.Search in Google Scholar

32. Rite, S, Baldellou, A, Giraldo, P, Labarta, JI, Giralt, M, Rubio-Felix, D, et al.. Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res 2002;52:109–12. https://doi.org/10.1203/00006450-200207000-00020.Search in Google Scholar

33. Kaplan, P, Mazur, A, Manor, O, Charrow, J, Esplin, J, Gribble, TJ, et al.. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149–53. https://doi.org/10.1016/s0022-3476(96)70203-2.Search in Google Scholar

34. Zevin, S, Abrahamov, A, Hadas-Halpern, I, Kannai, R, Levy-Lahad, E, Horowitz, M, et al.. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med 1993;86:565–73.Search in Google Scholar

35. Bembi, B, Zanatta, M, Carrozzi, M, Baralle, F, Gornati, R, Berra, B, et al.. Enzyme replacement treatment in type 1 and type 3 Gaucher’s disease. Lancet 1994;344:1679–82. https://doi.org/10.1016/s0140-6736(94)90462-6.Search in Google Scholar

36. Drelichman, G, Ponce, E, Basack, N, Freigeiro, D, Aversa, L, Graciela, E, et al.. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151:197–201. https://doi.org/10.1016/j.jpeds.2007.02.057.Search in Google Scholar PubMed

37. Oliveira, MC, Oliveira, BM, Queiros, E, Viana, MB. Clinical and nutritional aspects of Gaucher disease: prospective study of 13 children at a single center. J Pediatr 2002;78:517–22. https://doi.org/10.2223/jped.909.Search in Google Scholar

38. Mendelsohn, E, Meir, A, Abrahamov, A, Elstein, D, Zimran, A, Levy-Khademi, F. Growth and final height of children with Gaucher disease: a 15-year followup at an Israeli Gaucher centre. Blood Cells Mol Dis 2018;68:97–9. https://doi.org/10.1016/j.bcmd.2016.11.014.Search in Google Scholar PubMed

39. Cheung, R, Sillence, O, Tchan, MC. Homocysteine and erythrocyte sedimentation rate correlate with cerebrovascular disease in Fabry disease. JIMD Rep 2012;3:101–5. https://doi.org/10.1007/8904_2011_123.Search in Google Scholar PubMed PubMed Central

40. Tiago Koppe, T, Doneda, D, Siebert, M, Paskulin, L, Camargo, M, Tirelli, KM, et al.. The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease. Genet Mol Biol 2016;39:30–4. https://doi.org/10.1590/1678-4685-gmb-2015-0125.Search in Google Scholar PubMed PubMed Central

41. Stirnemann, J, Boutten, A, Vincent, C, Mekinian, A, Heraoui, D, Fantin, B, et al.. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease Blood Cells. Mol Dis 2011;46:34–8. https://doi.org/10.1016/j.bcmd.2010.10.014.Search in Google Scholar PubMed

Received: 2021-11-04

Accepted: 2022-02-08

Published Online: 2022-03-03

Published in Print: 2022-04-26

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/jpem-2021-0664

Keywords for this article

endocrinology; Fabry disease; Gaucher disease